- $3.11bn
- $3.01bn
- $158.32m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19.04 | ||
| PEG Ratio (f) | 1.67 | ||
| EPS Growth (f) | 12.85% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.96 | ||
| Price to Tang. Book | 16.53 | ||
| Price to Free Cashflow | 21.08 | ||
| Price to Sales | 6.9 | ||
| EV to EBITDA | 17.71 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 50.68% | ||
| Return on Equity | 131.82% | ||
| Operating Margin | 37.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 12.85 | 15.94 | 17.49 | 14 | 158.32 | 717 | 665.58 | 192.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -23.99 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Liquidia Corporation is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The Company operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT‑engineered inhaled dry‑powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler.
Directors
- Stephen Bloch NEC (59)
- Roger Jeffs CEO (60)
- Michael Kaseta CFO (45)
- Robert Lippe COO (56)
- Scott Moomaw SVP (51)
- Russell Schundler GCN
- Tushar Shah OTH (61)
- Damian deGoa DRC (42)
- Joanna Horobin IND (66)
- David Johnson IND (38)
- Arthur Kirsch IND (69)
- Paul Manning IND (65)
- Katherine Rielly-Gauvin IND (58)
- Raman Singh IND (50)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 17th, 2020
- Public Since
- July 26th, 2018
- No. of Shareholders
- 1,000
- No. of Employees
- 216
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 89,508,891
- Address
- 419 Davis Drive, Suite 100, MORRISVILLE, 27560
- Web
- https://www.liquidia.com/
- Phone
- +1 3026365401
- Auditors
- PricewaterhouseCoopers LLP
Latest News for LQDA
Upcoming Events for LQDA
Q3 2026 Liquidia Corp Earnings Release
Q4 2026 Liquidia Corp Earnings Release
Similar to LQDA
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
As of Today at 03:49 UTC, shares in Liquidia are trading at $34.78. This share price information is delayed by 15 minutes.
Shares in Liquidia last closed at $34.78 and the price had moved by +50.17% over the past 365 days. In terms of relative price strength the Liquidia share price has outperformed the S&P500 Index by +28.55% over the past year.
The overall consensus recommendation for Liquidia is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLiquidia does not currently pay a dividend.
Liquidia does not currently pay a dividend.
Liquidia does not currently pay a dividend.
To buy shares in Liquidia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $34.78, shares in Liquidia had a market capitalisation of $3.11bn.
Here are the trading details for Liquidia:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LQDA
Based on an overall assessment of its quality, value and momentum Liquidia is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Liquidia is $56.88. That is 63.54% above the last closing price of $34.78.
Analysts covering Liquidia currently have a consensus Earnings Per Share (EPS) forecast of $2.26 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Liquidia. Over the past six months, its share price has underperformed the S&P500 Index by -19.11%.
As of the last closing price of $34.78, shares in Liquidia were trading -35.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Liquidia PE ratio based on its reported earnings over the past 12 months is 19.04. The shares last closed at $34.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Liquidia's management team is headed by:
- Stephen Bloch - NEC
- Roger Jeffs - CEO
- Michael Kaseta - CFO
- Robert Lippe - COO
- Scott Moomaw - SVP
- Russell Schundler - GCN
- Tushar Shah - OTH
- Damian deGoa - DRC
- Joanna Horobin - IND
- David Johnson - IND
- Arthur Kirsch - IND
- Paul Manning - IND
- Katherine Rielly-Gauvin - IND
- Raman Singh - IND